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Host protection against several intracellular pathogens requires the induction of CD8+ T
cell responses. CD8+ T cells are potent effector cells that can produce high amounts of
pro-inﬂammatory cytokines and kill infected target cells efﬁciently. However, a protective
role for CD8+ T cells during Leishmania infections is still controversial and largely depends
on the infection model. In this review, we discuss the role of CD8+ T cells during various
types of Leishmania infections, following vaccination, and as potential immunotherapeutic
targets.
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INTRODUCTION
CD8+ T cells play a major role in protective immunity to a wide
variety of pathogens, including viruses, bacteria, and protozoan
parasites. However, the protective role of CD8+ T cells dur-
ing Leishmania infections has been controversial, mainly because
of the discrepancy among infections with different Leishmania
species. Different Leishmania species have different tropisms and
their diversity is reﬂected in the various clinical manifestations
they induce. Hence, it is not surprising that the contribution of
CD8+ T cells to the immune response against the parasite depends
on the clinical form and the species that is causing it. Here, we dis-
cuss the literature on the contribution of CD8+ T cells to the
immune response against Leishmania, taking into account the
various clinical forms and experimental models.
CD8+ T CELL FUNCTIONS
CD8+ T cells recognize peptides that are presented in the context
of major histocompatibility complex (MHC) class I molecules via
the T cell receptor (TCR). Although peptides presented via MHCI
mainly derive from endogenous antigens, various exogenous cell-
associated antigens have also been shown to be uploaded onto
the MHCI pathway, by a process referred to as cross-presentation.
Leishmania antigens were also shown to be cross-presented (Bert-
holet et al., 2006). During in vivo infections, cross-presentation of
Leishmania antigens may result from several internalization path-
ways, such as direct infection, receptor-mediated uptake (Woel-
bing et al., 2006), or internalization of apoptotic vesicles (Winau
et al., 2006). Thus far, two different processing pathways have been
proposed. An early work demonstrated that a surface antigen of
L. amazonensis was processed in a proteasome-dependent manner
within the cytosol (Kima et al., 1997). In contrast, a more recent
study showed that cross-presentation of secreted leishmanial anti-
gens is conﬁned to an intraphagosomal processing pathway that is
TAP- and proteasome-independent (Bertholet et al., 2006).
After activation, antigen-speciﬁcCD8+ T cells differentiate into
effector cells and acquire the capacity to kill target cells, and pro-
duce several cytokines and chemokines (Kaech et al., 2002; Harty
andBadovinac,2008).Among the variousCD8+ Tcell subsets,Tc1
were shown to play a major role in the ﬁght against several pro-
tozoan parasites (Jordan and Hunter, 2010). The hallmark of this
subset is the production of IFN-γ and TNF, and cytotoxic capacity
(Woodland and Dutton, 2003). The precise mechanism under-
lying cytotoxic T lymphocyte (CTL) killing of microbes is still
poorly understood. CTLs can exert cytotoxicity through various
mechanisms: via exocytosis of lytic granula containing perforin,
granzymeA/B,and/or granulysin; through the interactionbetween
FasL andFas expressed on targets cells; via TNF; or via TRAIL (Tra-
pani and Smyth, 2002). A study has also shown that reactivated
memory CD8+ T cells efﬁciently killed Listeria monocytogenes
via a mechanism mediated by CCL3 and involving the induction
of radical oxygen intermediates (Narni-Mancinelli et al., 2007).
Direct killing of extracellular pathogen by CTLs has also been
described. For example, CTLs can mediate killing of Mycobac-
terium tuberculosis through the release of anti-bacterial products
(Stenger et al., 1998; Canaday et al., 2001). However, direct killing
of Schistosoma mansoni (Ellner et al., 1982) and Entamoeba his-
tolytica (Salata et al., 1987) is thought to be contact-dependent.
CTLs have also been reported to directly kill extracellular Toxo-
plasma gondii (Khan et al., 1990). Interestingly, killing in this case
appeared to be antigen-speciﬁc. To date there is no evidence that
CD8+ T cells can mediate protection against Leishmania parasites
through their cytotoxic activity. However, since CTLs have been
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observed in various mouse models and also in human patients, a
possible protective role for Leishmania-speciﬁc cytotoxic T cells
should not be excluded.
In addition to killing and releasing cytokines and chemokines,
recent studies have ascribed a novel regulatory role for CD8+ T
cells (Sun et al., 2009; Palmer et al., 2010; Trandem et al., 2011).
Regulatory CD8+ T cells represent a transient state of effector
CD8+ T cells (Trandem et al., 2011), which is possibly induced
by potent TCR stimulation, which promotes the production of
the immunosuppressive cytokine IL-10 (Zhang and Bevan, 2011).
Not only do these cells produce IL-10, but they are also excellent
killers and produce normal to higher amounts of IFN-γ and TNF
(Sun et al., 2009; Palmer et al., 2010; Trandem et al., 2011). The
main function of these cells is thought to lie in the prevention of
immunopathology during infection without affecting the kinet-
ics of pathogen clearance. IL-10-producing CD8+ T cells have
also been observed in human patients infected with L. guyanensis
(Bourreau et al., 2007) and in patients suffering from post-kala-
azar dermal leishmaniasis (PKDL;Ganguly et al., 2008). The role of
regulatory CD8+ T cells in the immune response against parasitic
infections is still unknown.
CD8+ T CELLS IN EXPERIMENTAL CUTANEOUS
LEISHMANIASIS
The role of CD8+ T cells in the immunity to L. major has always
been controversial. Early studies in BALB/c mice reported that
CD8+ T cells were the main mediators of protection following
CD4+ T cell depletion in mice infected with L. major (Titus et al.,
1987; Hill et al., 1989; Muller et al., 1991). Interestingly, depletion
of CD4+ T cells was rendering susceptible BALB/c mice resis-
tant to L. major infection. The results obtained using the CD4+ T
cell depletion model suggested that CD8+ T cells could potentially
control L. major infection inmice.A few years later, experiments in
β2-microgobulin-deﬁcient mice contradicted these ﬁndings and
revealed that CD8+ T cells were not essential in mediating pro-
tection in L. major-infected BALB/c mice (Wang et al., 1993).
Moreover, a study in CD8+ T cell-deﬁcient mice demonstrated
that Cd8−/− mice were able to control L. major infection for
at least 1 year, suggesting that CD8+ T cells were not required
for long-lasting immunity (Huber et al., 1998). The contribution
of CD8+ T cells in the control of primary L. major infection
became less important also because of the strong evidence that
Th1 cells were the primary cells involved in mediating protection
against cutaneous leishmaniasis (Reiner and Locksley, 1995; Louis
et al., 1998; Sacks and Noben-Trauth, 2002). Several studies have
demonstrated that Th1 cells producing IFN-γ were essential in
controlling L. major infection, and that failure to develop a Th1
response resulted in susceptibility to the diseases. Hence, a consen-
suswas reached in that if amouse generates Th2 responses, thiswill
lead to susceptibility; in contrast, Th1 responses were successfully
controlling infection without the help of CD8+ T cells.
This paradigm was later challenged when new ﬁndings arose
from amore naturalmodel of infection,where 100metacyclic pro-
mastigotes were inoculated intradermally in the ears of C57BL/6
mice. In this model, Cd8−/− and CD8+ T cell-depleted mice fail
to control L. major infection, and CD8+ T cells were thought to
be necessary for supporting Th1 responses (Belkaid et al., 2002).
The discrepancy between the ﬁndings in the low- and the high-
parasite dose model was clariﬁed by another work that compared
the requirements of CD8+ T cells in both systems (Uzonna et al.,
2004). Interestingly, in the low infection model CD8+ T cells pro-
ducing IFN-γwere essential formodulatingCD4+ T cell responses
toward a Th1 response. In contrast, C57BL/6 mice inoculated with
a high L. major dose did not require CD8+ T cell help to gener-
ate protective Th1 responses. The CD8+ T cell requirement for
optimal IFN-γ production by Th1 cells was also proposed in a
high-dose L. major infection model in BALB/c mice (Herath et al.,
2003). Moreover, CD8+ T cell-derived IFN-γwas reported to con-
tribute to the induction of nitric oxide production inmacrophages
during experimental cutaneous leishmaniasis (Stefani et al., 1994).
Although the role of CD8+ T cells-derived IFN-γ has been clar-
iﬁed, little is known about the involvement of cytotoxic CD8+ T
cells in cutaneous leishmaniasis. In a low-dose model of L. major
infection, CD8+ T cell responses were shown not only to be pro-
tective, but also to mediate pathology (Belkaid et al., 2002). Hence,
it is possible that CTLs may be involved in the ulceration of skin
lesions through tissue disruption. This suggests that perhaps two
types of CD8+ T cell effectors are generated during L. major infec-
tion: antigen-speciﬁc CD8+ T cells that produce IFN-γ but lack
cytotoxic activity; and CTLs that are potent killers but produce
little to no IFN-γ and promote pathology.
Although the role of CD8+ T cells during primary immune
responses is controversial, these cells appear to play a prominent
role in protecting mice from a secondary challenge (Muller et al.,
1993, 1994). Indeed, antigen-speciﬁcCD8+ T cells were expanding
up to 50-fold in the spleen and lymph nodes of reinfected BALB/c
mice (Muller et al., 1994). This expansion correlated with a sub-
stantial production of IFN-γ, which is thought to be essential for
controlling Leishmania infections. These observations have major
implications for vaccine design.
In summary, during experimental cutaneous leishmaniasis,
CD8+ T cells are necessary to support protective Th1 responses
through IFN-γ production, but they are also involved in the devel-
opment of immunopathology. Further investigations are needed
tobetter identify various subtypes of CD8+ Tcells that arise during
cutaneous leishmaniasis.
CD8+ T CELLS IN EXPERIMENTAL VISCERAL LEISHMANIASIS
In contrast to the cutaneous models, CD8+ T cells have always
been thought to play a major role in experimental visceral leish-
maniasis (VL). Over 20 years ago, Stern et al. (1988) demonstrated
for the ﬁrst time that CD8+ T cells signiﬁcantly contribute to
the formation of granulomas in the liver of L. donovani-infected
mice. Indeed, CD8+ T cell depletion resulted in impaired gran-
uloma formation and exacerbation of liver disease. In agreement
with these results, Kaye et al. (1992) also reported a delayed onset
and a decrease of the liver granulomatous response in non-obese,
diabetic mice expressing transgenic I–E molecules, suggesting that
antigen-speciﬁc CD8+ T cells are required for proper granuloma
formation. CD8+ T cells appear to participate in controlling par-
asite growth in the spleen as well, since CD8+ T cell depletion
during chronic VL signiﬁcantly increased splenic parasite burden
(Stäger, unpublished). This observation was underscored by the
fact that adoptive transfer of antigen-speciﬁc CD8+ T cells during
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chronic L. donovani infection resulted in 90% reduction in the
splenic parasite burden (Polley et al., 2006). Moreover, therapeu-
tic vaccination aimed at reactivating CD8+ T cells during chronic
VL ensued in the control of parasite growth in the spleen (Joshi
et al., 2009).
Interestingly, CD8+ T cells do not only participate in primary
responses to L. donovani, but are also the major mediators of resis-
tance upon reinfection (Stern et al., 1988). Indeed, protection was
abrogated following CD8+ T cell but not CD4+ T cell depletion.
A prominent function for CD8+ T cells was also described in
L. infantum-infected mice. Using an intradermal infection model,
Ahmed et al. (2003) demonstrated that CD8+ T cells contribute
to parasite clearance in the skin of L. infantum-infected mice.
Another study also showed that CD8+ T cells puriﬁed from L.
infantum-infected mice expressed IFN-γ and TNF, and displayed
considerable cytotoxic activity against cells expressing Leishmania
antigens (Tsagozis et al., 2003). Interestingly, killing of infected
target cells was mediated by both the perforin and Fas/FasL path-
ways (Tsagozis et al., 2003). The Fas/FasL pathway has also been
implicated in the defense against L. donovani (Alexander et al.,
2001). Indeed, gld and lpr mice, which lack a functional Fas/FasL
pathway, were shown to be more susceptible to L. donovani.
Additionally to the classical cytotoxic pathways, a novel coun-
terregulatory function for a subset of cytotoxic CD8+ T cells has
recently been proposed in the L. donovani infectionmodel (Martin
et al., 2010). In this study, CD3+CD8+CD40+ T cells are shown
to suppress regulatory T cells via CD40/CD40L interaction dur-
ing the early stages of infection in BALB/c mice. CD40 signals
through Ras, PI3K, and protein kinase C, leading to the induction
of granzyme and perforin, and ultimately to the killing of Tregs.
CD8+ T cells may not be merely participating in the pri-
mary immune response by secreting IFN-γ and possibly killing
infected target cells and/or Tregs, but they could also be involved
in the recruitment of inﬂammatory cells and in the maintenance
of granulomas. Indeed, a study using L. infantum demonstrated
that CD8+ T cells expressed RANTES and MIP-1α (Tsagozis et al.,
2003), two chemokines that are involved in the recruitment of T
cells at the inﬂammatory site and in the formation and mainte-
nance of granulomas (Mackay, 2001). The authors proposed that
CD8+ T cells may thus be involved in granuloma formation. This
hypothesis is in agreement with the depletion data (Stern et al.,
1988), showing that depletion of CD8+ T cells results in impaired
granuloma formation and ultimately in disease exacerbation.
Despite the documented evidence that CD8+ T cells strongly
participate in the immune response to L. donovani and L. infan-
tum, our recent ﬁndings suggest that L. donovani induces defective
antigen-speciﬁc CD8+ T cell responses (Joshi et al., 2009). Inter-
estingly, mice infected with L. donovani generate CD8+ T cell
responses with limited clonal expansion. The extension of the
clonal expansion is thought to be correlated with the effectiveness
in eliminating pathogens. Itwas calculated that a naïveCD8+ Tcell
may go through 19 cell divisions in the ﬁrst week after pathogen
inoculation (Badovinac et al., 2007). Massive clonal expansions
have not only been observed during viral infections, but also
following the injection of irradiated Plasmodium berghei sporo-
zoites (Sano et al., 2001). During L. donovani infection, CD8+
T cells underwent at least 8–9 rounds of division, but failed to
accumulate in the spleen (Joshi et al., 2009).Moreover,only 10%of
CD8+ T cells during clonal expansion expressed markers typically
associated with end-differentiated effector cells, such as KLRG1,
PD-1 and Fas (Bankoti and Stäger, unpublished). The cause of
this limited expansion is yet unknown and may depend on sev-
eral factors. One of the possible explanations is limited antigen
availability that may result from poor antigen-processing and pre-
sentation. Processing of Leishmania antigens is thought to be
conﬁned to a TAP-independent, intraphagosomal pathway that
is less efﬁcient and requires higher amounts of antigen than the
endoplasmic reticulum-based, TAP-dependent cross-presentation
pathway (Bertholet et al., 2006). Furthermore, the major surface
protease of Leishmania, gp63, was shown to cleave epitopes within
the parasitophorous vacuole, further reducing antigen availability
(Garcia et al., 1997). Hence, Leishmania antigens may be poorly
presented and this poor presentation may not be enough to induce
and sustain a massive clonal expansion of antigen-speciﬁc CD8+
T cells.
Nonetheless, antigen may be suddenly available in large
amounts later on during L. donovani infection, since CD8+ T cells
undergo a second round of activation, become dysfunctional, and
ultimately die by “exhaustion” (Joshi et al., 2009); high antigen
levels have been described as a cause of CD8+ T cell “exhaus-
tion” during chronic viral infections (Mueller and Ahmed, 2009).
Further research is needed to clarify the mechanisms involved in
CD8+ T cell exhaustion during chronic VL.
In conclusion, CD8+ T cells are required to control para-
site growth during experimental VL and reactivation of these
responses results in a dramatic reduction in parasite bur-
den. Therefore, immune interventions that target CD8+ T cell
responses may have great therapeutic potential against VL.
CD8+ T CELLS AND HUMAN LEISHMANIA INFECTIONS
The role of CD8+ T cells in human leishmaniasis patients is still
unclear and seems to depend on the various species of parasites
and the disease they cause.
Few studies have been conducted with human VL patients.
However, most of the studies ascribe a protective role for CD8+ T
cells, in agreement with results obtained from experimental mod-
els. Indeed, the control of L. infantum infection was shown not
only to be associated with IFN-γ-producing CD4+ T cells, but
also with CD8+ T cells (Mary et al., 1999). Interestingly, during
active VL, CD8+ T cells are less responsive to stimulation and
a greater percentage stains positive for Annexin V compared to
healthy controls (Clarencio et al., 2009). These observations cor-
relate very well with what we observed in mice experimentally
infectedwith L. donovani,whereCD8+ T cells became increasingly
dysfunctional during chronic infection and died by exhaustion
(Joshi et al., 2009). Whether human CD8+ T cells also display
signs of exhaustion during active VL still remains to be tested.
Another study investigating CD8+ T cell responses in patients
infected with L. chagasi has revealed that the frequency of
CD18+CD45RO+ CD8+ T cells is signiﬁcantly decreased in the
spleen of patients with active VL (Clarencio et al., 2009). In con-
trast,CD18+ CD8+ T cells seem to be retained in the bonemarrow
of VL patients. CD18, or integrin β-2, is the β subunit of LFA-1
(CD11a), CD11b, CD11c, and CD11d. In humans, lack of CD18
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causes leukocyte adhesion deﬁciency, a disorder characterized by
lack of leukocyte extravasation fromblood into the tissue (Bunting
et al., 2002). With exception of the fact that CD18+ cells appear
in the granulomas of dogs with asymptomatic VL (Sanchez et al.,
2004), very little is known about the function of CD18+ CD8+ T
cells during VL and whether cells lacking CD18 expression have
similar migratory capacity and effector functions to their CD18+
counterparts.
Not only is the frequency of CD18+ CD8+ T cells reduced in
L. chagasi patients, but also, the level of circulating memory T
cells is signiﬁcantly decreased during active VL (Hailu et al., 2005;
Clarencio et al., 2009). This observation is in agreement with our
ﬁndings in the experimental model of VL, where the majority of
the CD8+ T cells displayed an effector phenotype during chronic
infection (Joshi et al., 2009).
Although CD8+ T cells positively correlate with cure of VL
patients, one report suggested that these cells may contribute to
the immunopathogenesis of PKDL (Ganguly et al., 2008). Indeed
patients suffering from PKDL showed a signiﬁcant increase in
the percentage of CD8+ T cells producing IL-10, which disap-
peared after cure (Ganguly et al., 2008). IL-10-secreting CD8+ T
cells are thought to play a regulatory role in different viral infec-
tion models. This CD8+ T cell subset was shown to display great
cytotoxicity and produce granzyme B, IFN-γ, and TNF (Sun et al.,
2009; Palmer et al., 2010; Trandem et al., 2011). IL-10+ CD8 T cells
seem to represent a transient and reversible state of CD8+ effector
T cell differentiation. Its primary function is to balance pathogen
clearance with bystander tissue damage (Zhang and Bevan, 2011).
Interestingly, in viral model, this subset disappears after the infec-
tion is cleared.Hence, it is possible that the IL-10-producingCD8+
T cells in PKDL patients are actually killing parasites and protect-
ingpatients from tissuedamage, rather than suppressingprotective
responses. Further studies are needed in order to deﬁne the nature
of these cells.
CD8+ T cells also actively participate in the immune response
to cutaneous infections in human. As observed in the low-dose
model in mice (Belkaid et al., 2002; Uzonna et al., 2004), L. major
also induces Th1 and CD8+ T cells in human patients and both
responses are associated with disease resolution (Nateghi Rostami
et al., 2010). CD8+ T cells were not only observed in large numbers
in the lesions of L. major patients during the acute phase, but also
during thehealingprocess (Da-Cruz et al.,1994,2002,2005;Gaafar
et al., 1999). The exact role of CD8+ T cells in L. major infec-
tions in humans is not yet known. A major correlate of protection
appears to be thehigh amounts of IFN-γproducedbyCD8+ Tcells
after restimulation (Nateghi Rostami et al., 2010). In vitro studies
have also demonstrated that Leishmania-speciﬁc CTLs are gener-
ated upon co-culturing human naïve T cells with antigens from L.
amazonensis promastigotes and IL-12 (Russo et al., 1999), or with
L. major parasites (Da Conceicao-Silva et al., 1994). Moreover,
increased granzyme B activity was also found in patients with an
active infection andwas associatedwith a good prognosis (Bousof-
fara et al., 2004). In this study, in vitro cytotoxicity by peripheral
blood lymphocytes on L. major-infected macrophages appeared
to be mediated by granzyme B, suggesting that CTL activity may
be involved in controlling parasite growth. It is possible, though,
that the cytotoxic activity not only contributes to disease clearance,
but also to the development of skin ulceration, as observed in L.
major-infected mice (Belkaid et al., 2002).
A strong CD8+ T cell expansion has also been observed in L.
mexicana patients during the healing process (Salaiza-Suazo et al.,
1999). Interestingly, lesions of patients with localized cutaneous
leishmaniasis (LCL) harbor a higher number of CD8+ T cells
compared to patients with diffuse cutaneous leishmaniasis (DCL;
Hernandez-Ruiz et al., 2010). As already observed in VL patients,
CD8+ T cells inDCL patients, unlike LCL patients, show a reduced
capacity to respond to antigen-speciﬁc stimulation during active
infection. In fact, these cells displayed low cytotoxicity and only
produced little IFN-γ upon stimulation, therefore showing typi-
cal signs of functional exhaustion (Hernandez-Ruiz et al., 2010).
Strikingly, effector functions could be restored in vitro after stim-
ulation with TLR2 agonists, highlighting the potential therapeutic
beneﬁt of the revival of CD8+ T cell functions in DCL patients.
In contrast to the cutaneous and visceral forms of leishmania-
sis –whereCD8+ Tcells seem to correlatewith cure and contribute
to the immune response – in mucocutaneous infections (ML)
CD8+ T cells seem to be implicated in the pathogenesis of the
disease. Indeed, high numbers of cytotoxic CD8+ T cells were
observed in ML patients (Barral-Netto et al., 1995; Brodskyn et al.,
1997). Moreover, the recruitment of granzyme A+ CD8+ T cells is
associated with lesion progression (Faria et al., 2009), suggesting
that CTLsmay contribute to immunopathology. The development
of ML is not only associated with the presence of CTL, but also
with a high frequency of activated CD4+ T cells, an extreme IFN-
γ and TNF production, and a reduced control of inﬂammation
due to low expression of the IL-10 receptor (Gaze et al., 2006;
Faria et al., 2009). Furthermore, IL-17-secreting CD4+ and CD8+
T cells were also found in ML patients (Boaventura et al., 2010).
Consequently, neutrophils, which are typically recruited during
a TH17-mediated inﬂammatory response, were also detected in
necrotic and perinecrotic areas (Boaventura et al., 2010). This
suggests that neutrophils, together with CTLs, may be involved
in tissue injury and in the development of immunopathology.
Taken together, the literature shows that CD8+ T cells actively
participate in the ﬁght against most Leishmania infections in
humans and their presence correlates with cure. In contrast,CD8+
T cells in ML patients contribute to disease exacerbation.
CD8+ T CELLS AND THEIR ROLE IN FUTURE VACCINE
DEVELOPMENT
Vaccination of humans with heat-killed Leishmania or recom-
binant parasite proteins has so far failed to induce long-term
immunity and only recovery from natural or experimental infec-
tion has provided proper protection. Several trials have analyzed
theprotective effect of autoclavedL.major plusBacillus-Calmette–
Guérin (BCG) versus BCG alone assessing the cumulative inci-
dence of cutaneous leishmaniasis caused by L. tropica (Shariﬁ
et al., 1998) or L. major (Momeni et al., 1999), or of VL (Khalil
et al., 2000) caused by L. donovani. Although no trial showed a
signiﬁcant effect on disease incidence, the vaccination induced
skin test conversion and provided limited protection. Addition-
ally, a study showed that immunization of Colombian soldiers
with three doses of L. amazonensis alonewas non-protective (Velez
et al., 2005).
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In the human disease, there is evidence that mixed T helper
cytokine proﬁles are present, while healing and protection against
reinfection are associated with dominant Th1 and CD8+ T cells.
These ﬁndings suggest that it is the cytokine balance that activates
or suppresses activation of macrophages harboring Leishmania
parasites. This, in turn, determines the outcome of the infection.
Thus treatments or antigen/adjuvant formulations that can alter
the type of T helper response may change the course of disease
(Da-Cruz et al., 2002;Rogers andTitus, 2004;Mohajery, 2007). For
this purpose, different vaccination strategies have been examined
in animal models including leishmanization (Modabber, 1990),
killed parasite (Grimaldi, 1995), live attenuated parasite (Titus
et al., 1995), and subsequently, subunit vaccines composed of
recombinant or native proteins from different stages of the para-
site’s life cycle, and DNA vaccines (Skeiky et al., 1998; Webb et al.,
1998; Stager et al., 2000; Bottrel et al., 2001; Campos-Neto et al.,
2001; Rafati et al., 2001; Coler et al., 2002). The latter two strate-
gies encompass candidates such as gp63, gp46, LACK, CPB, CPA,
Kmp11, LmsTI1, TSA, LeIF, HASPB1, and LPG, and have shown
promising results in murine models. Nonetheless, only Leish111f
(a recombinant fusion protein of LmsTI1, TSA, and LeIF) pro-
gressed through phase I and II clinical trials (Llanos-Cuentas et al.,
2010; Chakravarty et al., 2011).
Nowadays, it is clear that CD8+ T cells play an important role in
themechanisms for cure of and resistance to Leishmania infection,
either by production of IFN-γ and activation of macrophages, or
by direct killing of parasitized macrophages, or a combination of
both effects. CD8+ T cells have been associated with protection
against Leishmania reinfection in murine models; however, the
induction of these T cell subsets in humans seems to be also related
to the healing process. Today, there are several reports about differ-
ent leishmanial antigens eliciting CTL responses such as P8, gp46
(Colmenares et al., 2003), HASPB1 (Stager et al., 2000), Kmp11
(Basu et al., 2007), CPB (Rafati et al., 2002), nucleosomal histones
(Iborra et al., 2004), LmaCIN (Farajnia et al., 2005), LmsTI1, and
TSA (Coler et al., 2002).
The essential point to be considered in vaccine design for a
heterogeneous population, such as that of humans, is the HLA
polymorphism. Effective vaccination against a complex parasitic
infection such as Leishmania would require a multivalent vaccine
composed of several antigens to enhance the possibility of cover-
ing a good number of MHC types. This is possible either through
recombinant fusion proteins encompassing the whole antigen or
through vaccines composed of peptides from different antigens
(Campos-Neto et al., 2001; Rafati et al., 2001; Mendez et al., 2002).
The latter strategy, called polytope vaccine, is ﬁnding its way in
vaccinology because of its extraordinary properties, especially the
ability to direct the immune response toward the induction of
CTLs (Sbai et al., 2001; Schirmbeck et al., 2003; Robinson and
Amara, 2005).
As CTL responses play a pivotal role in defense against viruses
and tumor cells, polytope vaccines have found their way in these
ﬁelds but there is still no report on leishmaniasis even it has
been shown that CTLs could be very important in protection and
long-lasting resistance to infection. Recently, we took advantage of
the potential of immunoinformatics tools to screen for L. major
epitopes that could be presented in HLA A2, which is the most
prevalent HLA supertype in the Iranian population. In vitro stim-
ulation to recall memory CD8+ T cells from Leishmania-infected
individuals and intracellular cytokine assays for IFN-γ-producing
cells conﬁrmed that HLA A2 positive individuals that recovered
from an L. major infection successfully generated CD8+ T cell
responses against peptides derived fromLmsTI1 andLPG-3 (Seyed
et al., 2011). Furthermore, Walden and co-workers have mapped
the T cell epitopes from kinetoplastid membrane protein of L.
major (Kmp11) via classical mapping for different human HLA
class I alleles (Basu et al., 2007). Gazzinelli and co-workers have
studied CD8+ T cell responses against the Leishmania A2 antigen
and mapped the CD8+ T cell epitopes in BALB/c mice (Resende
et al., 2008). Laouini and co-workers (Guerfali et al., 2009) and
Dumonteil and co-workers (Dumonteil, 2009) started genome-
wide screenings for novel epitopes. Using a combination of T cell
epitope prediction tools, they successfully validated such epitopes
in both BALB/c and C57BL/6 mice.
CONCLUSION
Although understudied,CD8+ T cells appear to play an important
role in the immune response to most Leishmania infections. Pilot
studies in the murine model of VL have also demonstrated that
adoptive transfer of antigen-speciﬁc CD8+ T cells (Polley et al.,
2006) or reactivation of CD8+ T cell responses through a thera-
peutic vaccine (Joshi et al., 2009) results in the control of parasite
growth. A better understanding of the mode of activation, the
speciﬁcity, and effector functions of the various CD8+ T cell sub-
sets generated during Leishmania infections could ameliorate the
design of vaccines and of novel therapeutic interventions.
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